NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany.
The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in more than 80% of the patients, Dr. Georg Schett from University Clinic of Erlangen-Nuremberg and colleagues found.
“Tapering DMARDs including biological agents like TNF blockers is feasible in RA patients who are in remission for at least six months, and there are markers which can tell clinicians and patients about the risk for the relapse of disease when tapering DMARDs,” Dr. Schett tells Reuters Health by e-mail.
“This approach allows optimization of RA treatment and prevents overtreatment in certain patient groups. It gives a strategy and guidance in RA patients in remission. CCP antibody testing and MBDA testing are widely available in routine care in the U.S. Therefore, this strategy is ready for use,” he says.| | | Next → | Single Page